Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing new treatments for prostate cancer. It develops galeterone (TOK-001), an oral drug for the treatment of castration resistant prostate cancer (CRPC); and androgen receptor modulation optimized for response, which includes clinical program for the evaluation of galeterone (TOK-001) in patients with CRPC. Tokai Pharmaceuticals, Inc. was incorporated in 2004 and is based in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Gen-Probe Prodesse, Inc.||United States|
|PPD Discovery||United States|
|Neumedicines, Inc.||United States|
|BioServe Biotechnologies, Ltd.||United States|
|Mvi & Aquasol Branded Products Assets||United States|
Recent Private Companies Transactions
May 13, 2013
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Huntingdon County, PA | AstraZenecaPosted: Mar 14
- Fredericksburg, VA | AstellasPosted: Mar 07
- Princeton, NJ | RGPPosted: Mar 05
- Philadelphia, PA | PwCPosted: Apr 09
Sponsored Financial Commentaries
To contact Tokai Pharmaceuticals, Inc., please visit www.tokaipharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.